Roche’s ex-U.S. deal for Sarepta DMD programs could extend beyond micro-dystrophin gene therapy

After weathering one clinical failure in DMD this fall, Roche broadened its commitment to gene therapy by obtaining ex-U.S. rights to Sarepta’s micro-dystrophin-targeting program in a deal worth more than $1.1 billion up front. Roche also receives an option to gain territorial rights to additional DMD programs from Sarepta -- including both of its approved drugs.

Roche (SIX:ROG; OTCQX:RHHBY) will pay Sarepta $750 million in cash and purchase $400 million in equity. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is eligible for another $1.7

Read the full 802 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers